Post-COVID syndrome and type 2 diabetes mellitus in Kazakhstan: clinical manifestations and vaccine efficacy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: In this article, we report the results of a survey investigating post–coronavirus disease 2019 (COVID-19) syndrome in patients with type 2 diabetes mellitus and the impacts of vaccination on long-term manifestations. From February 2022 to April 2023, a survey of patients with type 2 diabetes and people without diabetes who were treated for a coronavirus infection was conducted in Kazakhstan.Methods: Participants were invited via social media to voluntarily participate in this study. A total of 417 surveys were included in this study, comprising 212 patients with type 2 diabetes and 205 without diabetes. We compared persistent complaints after recovery in patients with and without diabetes mellitus (DM), as well as vaccination status.Results: The results of this study on self-reported symptoms of prolonged COVID show that more than half of those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Kazakhstan have at least one persistent symptom after recovery. Based on the list of prolonged COVID-19 symptoms reported by patients with type 2 DM (T2DM), exertional dyspnoea, fatigue, respiratory discomfort, headaches, and sleep disturbances are among the most common ongoing conditions, and in many cases last more than 3 months after COVID-19.Conclusion: Patients with T2DM experience more severe and prolonged symptoms than those without diabetes. Additionally, vaccination lowers COVID-19 hospitalization risk and decreases the need for adjusting hypoglycemic therapy, such as insulin treatment, after recovering from SARS-CoV-2 infection.
Abstract
Purpose: In this article, we report the results of a survey investigating post–coronavirus disease 2019 (COVID-19) syndrome in patients with type 2 diabetes mellitus and the impacts of vaccination on long-term manifestations. From February 2022 to April 2023, a survey of patients with type 2 diabetes and people without diabetes who were treated for a coronavirus infection was conducted in Kazakhstan.Methods: Participants were invited via social media to voluntarily participate in this study. A total of 417 surveys were included in this study, comprising 212 patients with type 2 diabetes and 205 without diabetes. We compared persistent complaints after recovery in patients with and without diabetes mellitus (DM), as well as vaccination status.Results: The results of this study on self-reported symptoms of prolonged COVID show that more than half of those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Kazakhstan have at least one persistent symptom after recovery. Based on the list of prolonged COVID-19 symptoms reported by patients with type 2 DM (T2DM), exertional dyspnoea, fatigue, respiratory discomfort, headaches, and sleep disturbances are among the most common ongoing conditions, and in many cases last more than 3 months after COVID-19.Conclusion: Patients with T2DM experience more severe and prolonged symptoms than those without diabetes. Additionally, vaccination lowers COVID-19 hospitalization risk and decreases the need for adjusting hypoglycemic therapy, such as insulin treatment, after recovering from SARS-CoV-2 infection.
참고문헌 (37)
- "WHO coronavirus (COVID-19) dashboard" (2023)[URL]
- "Situation with coronavirus: officially" (2023)[URL]
- De Sire A, "Impact of rehabilitation on fatigue in post-COVID-19 patients : A systematic review and metaanalysis", Appl Sci, 12, pp.8593~ (2022)
- Pal R, "COVID-19 and diabetes mellitus : an unholy interaction of two pandemics", Diabetes Metab Syndr, 14, pp.513~517 (2020)
- Oronsky B, "A review of persistent post-COVID syndrome(PPCS)", Clin Rev Allergy Immunol, 64, pp.66~74 (2021)
- Nazarewska A, "Irritable bowel syndrome following COVID-19 : an underestimated consequence of SARS-CoV-2 infection", Pol Arch Intern Med, 132, pp.16323~ (2022)
- Lopez-Leon S, "More than 50 longterm effects of COVID-19 : a systematic review and metaanalysis", Sci Rep, 11, pp.16144~ (2021)
- "COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)" (2020)[URL]
- Huang C, "6-month consequences of COVID-19 in patients discharged from hospital : a cohort study", Lancet, 397, pp.220~232 (2021)
- Pan F, "Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19", Radiology, 302, pp.709~719 (2022)
- Wang X, "The clinical features and outcomes of discharged coronavirus disease 2019 patients : a prospective cohort study", QJM, 113, pp.657~665 (2020)
- Halpin SJ, "Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection : A crosssectional evaluation", J Med Virol, 93, pp.1013~1022 (2021)
- Gupta R, "Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases(Hypertension, diabetes etc)", Diabetes Metab Syndr, 14, pp.251~254 (2020)
- Raveendran AV, "2021. Post COVID-19 syndrome("Long COVID")and diabetes : Challenges in diagnosis and management", Diabetes Metab Syndr, 15, pp.102235~ (2021)
- Zheng C, "2021. Real-world effectiveness of COVID-19 vaccines : a literature review and meta-analysis", Int J Infect Dis, 114, pp.252~260 (2021)
- Ssentongo P, "SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19 : a systematic review and meta-analysis", BMC Infect Dis, 22, pp.439~ (2022)
- Oliynyk O, "Lack of difference in tocilizumab efficacy in the treatment of severe COVID-19 caused by different SARSCoV-2 variants", J Pers Med, 12, pp.1103~ (2022)
- Ciechanowicz P, "Skin and gastrointestinal symptoms in COVID-19", Przegl Gastroenterol, 15, pp.301~308 (2020)
- Fernández-de-Las-Peñas C, "Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors : a systematic review and meta-analysis", Eur J Intern Med, 92, pp.55~70 (2021)
- Subramanian A, "Symptoms and risk factors for long COVID in non-hospitalized adults", Nat Med, 28, pp.1706~1714 (2022)
- Jiang L, "One-year self-reported neurological sequelae in older COVID-19 survivors", Ageing Neurodegener Dis, 2, pp.10~ (2022)
- Dobrovanov O, "Pain in COVID-19 : Quis est culpa", Electron J Gen Med, 20, pp.em435~ (2023)
- Dmytriiev D, "Post-COVID pain syndrome", Anaesth, Pain Intensive Care, 25, pp.505~512 (2021)
- Whitaker M, "Persistent COVID-19 symptoms in a community study of 606, 434 people in England", Nat Commun, 13, pp.1957~ (2022)
- Fernández-de-Las-Peñas C, "Female sex is a risk factor associated with long-term post-COVID related-symptoms but not with COVID-19 symptoms : the LONG-COVID-EXP-CM multicenter study", J Clin Med, 11, pp.413~ (2022)
- Diaferio L, "Cross-sectional survey on impact of paediatric COVID-19 among Italian paediatricians : Report from the SIAIP rhino-sinusitis and conjunctivitis committee", Ital J Pediatr, 46, pp.146~ (2020)
- Izquierdo-Condoy JS, "Long COVID at different altitudes : a countrywide epidemiological analysis", Int J Environ Res Public Health, 19, pp.14673~ (2022)
- Kayaaslan B, "Post-COVID syndrome: A single-center questionnaire study on 1007 participants recovered from COVID-19", J Med Virol, 93, pp.6566~6574 (2021)
- Fernández-de-Las-Peñas C, "Diabetes and the risk of long-term post-COVID symptoms", Diabetes, 70, pp.2917~2921 (2021)
- Mittal J, "High prevalence of post COVID-19 fatigue in patients with type 2 diabetes : a case-control study", Diabetes Metab Syndr Clin Res Rev, 15, pp.102302~ (2021)
- "Pfizer vaccine can reduce COVID hospitalisation and death by 75%" (2021)[URL]
- Oliynyk OV, "Impact of alteplase on mortality in critically ill patients with COVID-19 and pulmonary embolism", Viruses, 15, pp.1513~ (2023)
- Amit S, "Early rate reductions of SARS-CoV-2 infection and COVID-19in BNT162b2 vaccine recipients", Lancet, 397, pp.875~877 (2021)
- Kuodi P, "Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms : cross-sectional study 2020-21, Israel", NPJ Vaccin, 7, pp.101~ (2022)
- Pal R, "Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus : a preliminary report", Diabetes Metab Syndr, 15, pp.193~196 (2021)
- Dispinseri S, "Robust neutralizing antibodies to SARSCoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia", J Clin Endocrinol Metab, 106, pp.1472~1481 (2021)
- Sourij C, "Humoral immune response to Covid-19vaccination in diabetes : Age-dependent but independent of type of diabetes and glycaemic control – the prospective COVAC-DM cohort study", Diabetes Obes Metab, 24, pp.849~858 (2022)